Drug Profile
Research programme: influenza virus vaccine - Immunitor USA
Latest Information Update: 28 Dec 2017
Price :
$50
*
At a glance
- Originator Immunitor USA
- Class Influenza virus vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for preclinical development in Influenza-virus-infections in USA (PO, Pill)
- 07 Dec 2015 Influenza virus vaccine is still in preclinical development in USA ( Immunitor pipeline, December 2015)
- 15 Nov 2010 Preclinical trials in Influenza virus infections in USA (PO)